Plus Therapeutics expands ReSPECT trial to MD Anderson Cancer Center

Plus Therapeutics announced that the University of Texas MD Anderson Cancer Center is now an active clinical trial site in its ongoing ReSPECT Phase 1 clinical trial, currently supported by the National Cancer Institute. ReSPECT is a multi-center, dose-finding study evaluating the Company's lead investigational asset, Rhenium NanoLiposome, in patients with recurrent glioblastoma. The study will be conducted by MD Anderson's Department of Neurosurgery with Jeffrey Weinberg, M.D., Professor of Neurosurgery and the Deputy Chair and Vice-Chair of Clinical Operations in The Department of Neurosurgery, as primary investigator. As the Company previously disclosed, the sixth dose escalation cohort of the ReSPECT trial is underway and expected to enroll by the end of 2020. In September 2020, the U.S. Food and Drug Administration granted both Orphan Drug designation and Fast Track designation to RNL for the treatment of patients with glioblastoma.